Skip to content

Spectrophon LTD Glucometry Monitor Accuracy

Accuracy Evaluation of Glucometry Monitor Developed by Spectrophon LTD

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03359629
Enrollment
210
Registered
2017-12-02
Start date
2017-09-27
Completion date
2017-10-16
Last updated
2019-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Glucose Metabolism Disorders

Keywords

Spectrophon, Glucose, Biosensor, Non-invasive testing

Brief summary

Diabetes mellitus (or diabetes) is a chronic, metabolic disease characterized by elevated levels of blood glucose. Patients with diabetes need to monitor their blood glucose level several times a day to control their medical state. Modern biosensors have become a promising solution for non-invasive blood glucose measurements. This study aims to validate the efficacy and the accuracy of Glucometry Monitor (NIGM) developed by Spectrophon LTD incorporated in smart watches. Method Participants will use Spectrophon biosensors to non-invasively estimate the level of glucose in blood. Blood will also be collected and the glucose level will be checked with commercially available blood glucose analyzers . All sets of data will be compared to estimate the accuracy of measurements of Spectrophon NIGM

Detailed description

Diabetes is a chronic, life-long disease that represents a major public health challenge at a world level (Matthews et al 1985). It is important to note that diabetes is common among mentally ill patients, especially among patients with schizophrenia that are treated with new generation antipsychotic drugs (Nielsen et al 2010, Vancampfort et al 2016). To maintain blood glucose level homeostasis, repeated blood glucose testing is needed. The vast majorities of currently available methods for blood glucose testing are invasive and cause discomfort for patients. However, biosensors have recently become a promising solution for non-invasive glucose blood testing (Bandodkar et al 2014; Zhang et al 2015). Spectrophon LTD has developed a technology that allows measurement of even the smallest amounts of various compounds contained in sweat. Using unique algorithm developed by Spectrophon LTD, these data provides the possibility of evaluating the levels of chemicals in the bloodstream. Based on this technology, Spectrophone LTD has developed a glucometer biosensor that is able to non-invasively detect the blood glucose level. This glucometer biosensor can be easily incorporated into most commercially available smartwatches. Development of this technology will allow real-time, non-invasive measurement of blood glucose level and will dramatically facilitate effective treatment of diabetes. In addition, this technology will enable monitoring of glucose levels in patients with mental disorders that will facilitate the early detection of metabolic syndrome. Study Design: this naturalistic study will examine the accuracy of Spectrophon NIGM incorporated in smart watch Samsung Gear S2 that non-invasively and indirectly detect the level of glucose in human blood. The study will be held in Maale Carmel Mental Health Center (MCMHC). Adult participants (n=200) will be recruited for the study from the staff of MCMHC (including doctors, nurses and administrative workers; no psychiatric in-patients will be recruited for the study). In parallel to glucose measurements with NIGM, blood will be collected and the glucose level will be checked using commercially available blood glucose analyzers. The participants will be able to select between two options for blood collection: The first option: intravenous cannula (Venflon) will be inserted in cubital vein and blood will be collected twice in the beginning and at the end of the procedure (within 1-3 hours) and checked for the glucose level with commercially available blood glucose analyzers. The second option: The blood will be collected twice from the cubital vein at the beginning and at the end of the procedure (within 1-3 hours) and checked for the glucose level using commercially available blood glucose analyzers . The measurements will be performed twice: before meal (subject should be in fasting state) and after meal with one hour interval between two measurements. The results of the measurements of the NIGM will be compared to the results obtained from commercially available blood glucose analyzers. The application automatically saves every measurement into archive. To better control the process, the manual fixation of data obtained by NIGM is performed.

Interventions

DEVICEYSI 2300 Stat Plus

Reference commercial glucometer

DEVICESpectrophon Glucometry Monitor

Wearable smartwatch with integrated non-invasive glucose detection system

Sponsors

Ariel University
CollaboratorOTHER
Tirat Carmel Mental Health Center
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* must be between ages 18 and 75 * must be able to sign informed consent form.

Exclusion criteria

* Acute psychotic state * Hepatitis * HIV * Tuberculosis * Haemophilia and other serious coagulation disorders * Significant impaired venous access * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Measurements With < 15% Error1-3 hoursDifference in measurements of blood glucose level obtained using Spectrophon glucometry monitor and commercially available glucose analyser YSI 2300

Countries

Israel

Participant flow

Participants by arm

ArmCount
Blood Collection (Healthy Individuals)
Participants's blood was collected and measured for glucose level before and after food intake
200
Blood Collection (Diabetic Patients)
Participants's blood was collected and measured for glucose level
10
Total210

Baseline characteristics

CharacteristicBlood Collection (Diabetic Patients)TotalBlood Collection (Healthy Individuals)
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
3 Participants15 Participants12 Participants
Age, Categorical
Between 18 and 65 years
7 Participants195 Participants188 Participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Israel
10 participants210 participants200 participants
Sex: Female, Male
Female
7 Participants121 Participants114 Participants
Sex: Female, Male
Male
3 Participants89 Participants86 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 2000 / 10
other
Total, other adverse events
0 / 2000 / 10
serious
Total, serious adverse events
0 / 2000 / 10

Outcome results

Primary

Percentage of Measurements With < 15% Error

Difference in measurements of blood glucose level obtained using Spectrophon glucometry monitor and commercially available glucose analyser YSI 2300

Time frame: 1-3 hours

ArmMeasureGroupValue (NUMBER)
Blood Collection (Healthy Individuals)Percentage of Measurements With < 15% ErrorAlgorithm 1.795.25 Percentage of measures with error <15%
Blood Collection (Healthy Individuals)Percentage of Measurements With < 15% ErrorAlgorithm 1.694.5 Percentage of measures with error <15%
Blood Collection (Diabetic Patients)Percentage of Measurements With < 15% ErrorAlgorithm 1.7100 Percentage of measures with error <15%
Blood Collection (Diabetic Patients)Percentage of Measurements With < 15% ErrorAlgorithm 1.6100 Percentage of measures with error <15%

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026